Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics reported Q2 2026 financial results and provided updates on its lead drug belapectin targeting MASH cirrhosis and portal hypertension. The company reached agreement with the FDA on key design elements of the planned registrational Phase 3 trial, validating its regulatory pathway. New clinical data reinforcing belapectin's poten…